Novartis CBYL719H12301 - "EPIK-B3"

Breast - EPIK-B3

Novartis CBYL719H12301 - "EPIK-B3"

Objective

A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation.

Principal Investigator(s)
David Chan, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials